Recently published studies correlated the MGMT status with clinical survival data: Based on promoter-wide methylation analyses of snap-frozen glioblastoma tissues using quantitative bisulfite sequencing and correlations with mRNA expression, protein expression and PFS, Shah et al. proposed a new classification scheme using methylation data from three different regions of the entire MGMT promoter, and provided confirmative data achieved by MS-MLPA. The gene discussed is MGMT; the disease is glioblastoma.